Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ondine Recruits First Patient for US Phase 3 Trial
Details : Nasal antimicrobial photodisinfection therapy consisiting of NF-031 (methylthioninium chloride & chlorhexidine gluconate) is being evaluated for treatment of surgical site infections.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2024
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Healthcare's Memorial Health University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Ondine Biomedical Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial
Details : Photodynamic Antimicrobial Chemotherapy (PACT) using methylene blue is a potential antimicrobial therapy that combines light and a photosensitizing drug, promoting a phototoxic effect on the treated cells increases membrane permeability in Candida albica...
Product Name : PACT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Healthcare's Memorial Health University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : SUNSTAR AMERICAS INC
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Periodontal Therapy on Patients With Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : SUNSTAR AMERICAS INC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : 3M Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of Patient Preoperative Preps In-vivo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : 3M Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Corsodyl
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2020
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2020
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2019
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable